SAN DIEGO, August 13, 2019 – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, today announced the appointment of Siva Mullapudi as Senior Director of CRO Services. Mr. Mullapudi joins ProSciento with more than 15 years of experience in clinical operations and global outsourcing management for the CRO industry.
As a member of the senior management team, Mr. Mullapudi oversees the strategy and continued expansion of the CRO Services Division at ProSciento, including clinical operations and project management.
“We are thrilled to have Siva join ProSciento’s senior management team. His experience in clinical operations and his expertise in implementing global expansion strategies is highly relevant as we continue to grow ProSciento’s operational footprint across Asia, Australia, Europe and South America,” said Brian Mooney, ProSciento’s Chief Operating Officer.
“ProSciento has earned an outstanding reputation in the industry for its metabolism focus and scientific expertise. I’m excited to join this highly respected clinical operations team and to be a part of continued strategic growth for the company,” said Mr. Mullapudi.
Mr. Mullapudi is an accomplished leader with an extensive track record in the CRO industry, much of it focused on developing and directing multinational phase I-IV clinical trial programs across Asia, Australia, Europe and North America. Prior to joining ProSciento, he served as Director of Clinical Development at Covance Inc., where he played an instrumental role in managing pipeline development and directing global clinical trials. Prior to this, Mr. Mullapudi was Associate Director of Project Management at Pharmaceutical Product Development, LLC (PPD), working with early development clients, alliance accounts and strategic partners, and managing client portfolios up to $55 million. In an earlier role, he managed all aspects from site start-up to study closeout activities for INC Research (now Syneos Health, Inc.). Mr. Mullapudi earned a master’s degree in biomedical engineering from Louisiana Tech University and an MBA with an emphasis on global healthcare operations from the University of Southern California’s Marshall School of Business.
About ProSciento, Inc.
ProSciento is a highly specialized clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally. For more information, please visit www.nashpass.wpengine.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
For business development inquires: